Navigation Links
Volcano Corporation Praises FAME Study Results
Date:9/23/2009

resident and CEO of Volcano. "Better patient outcomes and lower costs are key global objectives and central topics in the U.S. healthcare reform debate. This study demonstrates significant clinical and economic benefits of FFR when used routinely to guide treatments of multi-vessel disease."

FAME randomized 1,005 patients diagnosed with multi-vessel coronary artery disease at 20 European and United States centers to either angiography-guided PCI (n=496) or FFR-guided PCI (n=509) all using current drug regimens. Some physicians have been concerned that the lesions deferred by FFR may progress and cause future events. In the FAME study, 513 total lesions were deferred and only one of those lesions led to a myocardial infarction (heart attack) within two years (0.2 %). This highlights the effectiveness of using a 0.80 FFR threshold for triaging this multi-vessel disease patient population.

"FAME is among the most important studies in today's drug eluting stent era," said Huennekens. "FAME data has driven a significant increase in the use of FFR in the last year, but despite the clear and positive clinical and economic impact of FFR guided PCI, without direct reimbursement for FFR, physicians are often discouraged from using the tool because the line item cost for the FFR wires is perceived as an added expense to the hospital. This is a perfect example of where the current U.S. reimbursement system works against patients, physicians and hospitals because it drives doctors away from these beneficial and proven guidance tools. The data show that both patients and hospitals benefit, yet the reimbursement structure may be slowing adoption of the technology."

Volcano estimates that multi-vessel disease is treated in approximately 35% of all U.S. PCI (a combination of mutli-vessel stenting and patients who are staged and treated during two separate visits). By applying the FAME results across that patient populatio
'/>"/>

SOURCE Volcano Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Volcano Corporation Presentation at Weisel Conference to be Webcast
2. Volcano Corporation and Siemens Healthcare Announce Global Resale Agreement for Volcano IVUS/FFR Systems
3. Volcano Achieves Major Milestone in Japan Direct Sales Initiative With Signing of Termination Agreement With Goodman
4. Volcano Announces OCT Activities at EuroPCR 2009
5. Volcano Corporation Presentation at JMP Conference to be Webcast
6. Volcano Corporation Presentation at Bank of America/Merrill Lynch Conference to be Webcast
7. Volcano Corporation Announces Webcast of February 25th Analyst Day
8. Volcano Reports Full Year Revenues Increase 31 Percent
9. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
10. Volcano Highlights Commitment, Market Acceptance of FFR Product Line
11. Reminder: Volcano Corporation Schedules Conference Call, Webcast to Discuss Axsun Transaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Veretekk.com, Inc. announced today a strategic alliance ... Ocean Avenue has secured exclusive benefit to the strategic ... JM Ocean Avenue is a direct sales company ... and JM International, with partial ownership coming from JM ... , “After nearly 2 decades of servicing the industry ...
(Date:12/15/2014)... South Florida’s leading urgent care provider, MD ... daze of hassle, hustle, and bustle that can cause injuries ... burns when making special meals and heartburn after eating them, ... any time. To prevent this season of joy from becoming ... of helpful and healthful holiday tips to keep the season ...
(Date:12/15/2014)... Beltsville, MD (PRWEB) December 15, 2014 ... and services today released “ Social Media Cheat Sheets ... cultivating a community that drives results on the top ... a marketing program. It helps drive awareness, engagement, and ... conversions. For marketers to make an impact on new ...
(Date:12/15/2014)... Reinberg HealthDay Reporter FRIDAY, ... should reassure the millions of American women who have migraine: ... "There is no association between migraine and breast cancer ... medicine at Harvard Medical School. "There is no positive association, ... no protective effect either." About 18 percent of American ...
(Date:12/15/2014)... December 15, 2014 The increase in prevalence ... of the main factors which is contributing to the growth ... the diagnosis and treatment of hearing loss and balance disorders ... three parts - microphone, speaker and amplifier. The global market ... of 6.01% during the period from 2014 to 2019. Some ...
Breaking Medicine News(10 mins):Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
... , Anti-Abortion Extremist Ejected After "Murder" ... night in northern Virginia, Representative James Moran and Governor Howard Dean ... by thousands of people. Anti-abortion extremist Randall Terry, the founder of ... be there to disrupt it by accusing President Obama of "killing ...
... million acres in the southeastern United States, may sprout into ... the first evidence that root extracts from kudzu show promise ... metabolic syndrome that affects almost 50 million people in ... issue of ACS, Journal of Agricultural and Food Chemistry ...
... BATESVILLE, Ind., Aug. 26 Hill-Rom Holdings, Inc., (NYSE: HRC ) ... CEO, Hill-Rom, at the Thomas Weisel Partners Healthcare Conference in Boston on Thursday, ... , You are invited to listen to the live discussion via ... or access it directly at http://www.ver a ...
... , , , ... PRA International, a leading Clinical Research Organization, will host ... region in global clinical research studies. In this audio conference, ... discuss the benefits and challenges of managing clinical trials in ...
... , MORRIS PLAINS, N.J., Aug. 26 New entries ... care of their eyes. , , "Eye ... of several factors including indoor and outdoor irritants and allergens like dust, ... process," says Elise Brisco, O.D. "Since many people experience more ...
... , , , ... PPHM ) today announced that the U.S. National ... two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University ... of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic ...
Cached Medicine News:Health News:Randall Terry Removed By Police From Howard Dean Health Care Town Hall Meeting 2Health News:Hill-Rom to Participate at the Thomas Weisel Partners 2009 Healthcare Conference 2Health News:PRA International to Host Audio Conference 2Health News:Breakthroughs in Eye Care Products Offer Fresh Approach for Soothing Eyes 2Health News:NIAID Awards New Grant to Expand Studies of Peregrine's Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers 2Health News:NIAID Awards New Grant to Expand Studies of Peregrine's Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers 3Health News:NIAID Awards New Grant to Expand Studies of Peregrine's Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers 4Health News:NIAID Awards New Grant to Expand Studies of Peregrine's Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers 5
(Date:12/17/2014)... 17, 2014  Beamz Interactive, Inc. (OTCQB: BZIC), ... today announced that it has signed an agreement ... supplier of innovative prosthetic, orthotic and assistive technology ... the agreement, RSL Steeper will promote and supply ... for use within UK residential care facilities through ...
(Date:12/17/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... enrollment in its first Phase 2a study, RXI-109-1301.  ... the 1-month findings that were reported in September ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "MEMS Gyroscopes Analog ... Analysis" report to their offering. ... gyroscopes for tactical grade applications made a lot ... term of reliability. They are now accepted in ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
... trauma surgeon at Brooke Army Medical Center in San Antonio, ... announcement on April 28, 2011, that the U.S. Food and ... its CARDIOHELP System in the United States as a cardiac ... "The ability to bring environmental control and life ...
... Sciences, Inc., (GT) a privately held biotechnology company announced ... AND METHODS FOR CONSTRUCTING GENOMIC-BASED PHENOTYPIC MODELS" by the ... has a priority date of June 14, 2002 and ... modeling processes by which scientists may use computational models ...
Cached Medicine Technology:GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling 2GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: